[go: up one dir, main page]

IN2015KN00492A - - Google Patents

Info

Publication number
IN2015KN00492A
IN2015KN00492A IN492KON2015A IN2015KN00492A IN 2015KN00492 A IN2015KN00492 A IN 2015KN00492A IN 492KON2015 A IN492KON2015 A IN 492KON2015A IN 2015KN00492 A IN2015KN00492 A IN 2015KN00492A
Authority
IN
India
Prior art keywords
compounds
diseases
conditions
diabetes
infection
Prior art date
Application number
Inventor
Benjamin Jason Compton
Colin Malcolm Hayman
Ian Francis Hermans
David Samuel Larsen
Gavin Frank Painter
Regan James Anderson
Original Assignee
Callaghan Innovation Res Ltd
Benjamin Jason Compton
Colin Malcolm Hayman
Ian Francis Hermans
David Samuel Larsen
Gavin Frank Painter
Regan James Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callaghan Innovation Res Ltd, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Regan James Anderson filed Critical Callaghan Innovation Res Ltd
Publication of IN2015KN00492A publication Critical patent/IN2015KN00492A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection atopic disorders, autoimmune disease, diabetes or cancer.
IN492KON2015 2012-07-26 2013-07-26 IN2015KN00492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ60147312 2012-07-26
PCT/NZ2013/000133 WO2014017928A1 (en) 2012-07-26 2013-07-26 Organic compounds

Publications (1)

Publication Number Publication Date
IN2015KN00492A true IN2015KN00492A (en) 2015-07-17

Family

ID=49997620

Family Applications (1)

Application Number Title Priority Date Filing Date
IN492KON2015 IN2015KN00492A (en) 2012-07-26 2013-07-26

Country Status (9)

Country Link
US (1) US9586985B2 (en)
EP (1) EP2877481B1 (en)
JP (1) JP6528029B2 (en)
KR (1) KR102162619B1 (en)
CN (1) CN104736550B (en)
AU (1) AU2013293646B2 (en)
CA (1) CA2880191C (en)
IN (1) IN2015KN00492A (en)
WO (1) WO2014017928A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102235870B1 (en) * 2012-12-06 2021-04-07 빅토리아 링크 엘티디 Conjugate compounds
WO2014200363A1 (en) * 2013-06-10 2014-12-18 Victoria Link Limited Sphingoglycolipid analogues
WO2015187040A1 (en) * 2014-06-05 2015-12-10 Regan James Anderson Amino sphingoglycolipid analogues
JP6453033B2 (en) * 2014-10-22 2019-01-16 国立大学法人北海道大学 Method for producing sugar sphingosine and sphingo base
US9394312B1 (en) * 2015-06-14 2016-07-19 Mark Quang Nguyen Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
EP3374028B1 (en) * 2015-11-13 2021-05-26 La Jolla Institute for Allergy and Immunology Sphingamide compounds and methods for binding inkt cells
EP3434684A4 (en) * 2016-03-22 2019-11-27 Keio University COMPOUND OR ITS SALT, ACTIVATOR OF NATURAL T CELL CELLS, AND PHARMACEUTICAL COMPOSITION
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
JP2024510435A (en) 2021-03-18 2024-03-07 シージェン インコーポレイテッド Selective drug release from internalization complexes of bioactive compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4410913B2 (en) * 2000-06-12 2010-02-10 壽製薬株式会社 Process for producing novel glycolipid derivatives
AU2003225891A1 (en) * 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
JP3824319B2 (en) 2004-02-19 2006-09-20 株式会社紀文フードケミファ Antiviral composition
US20060024691A1 (en) 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
KR20120116511A (en) * 2004-08-27 2012-10-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 Ceramide derivatives as modulators of immunity and autoimmunity
CA2591232C (en) 2004-12-28 2014-10-21 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007035717A2 (en) * 2005-09-19 2007-03-29 The Rockefeller University Glycolipids and analogues thereof as antigents for nk t cells
WO2008047174A1 (en) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
US20080133801A1 (en) * 2006-12-04 2008-06-05 Aten International Co., Ltd. Keyboard-video-mouse switch system for switching between computers having a plurality of video sources each and switching method thereof
CN104478092B (en) 2007-04-12 2016-06-01 诺维信生物股份有限公司 Wastewater treatment
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
MX338827B (en) * 2008-10-08 2016-05-03 Vincent Serra Vaccine composition for use against influenza.

Also Published As

Publication number Publication date
US9586985B2 (en) 2017-03-07
AU2013293646A1 (en) 2015-03-12
KR20150073942A (en) 2015-07-01
AU2013293646B2 (en) 2017-10-19
CA2880191C (en) 2021-04-20
CA2880191A1 (en) 2014-01-30
CN104736550B (en) 2017-12-29
EP2877481A1 (en) 2015-06-03
US20150191503A1 (en) 2015-07-09
KR102162619B1 (en) 2020-10-08
WO2014017928A1 (en) 2014-01-30
EP2877481A4 (en) 2016-04-06
JP2015522656A (en) 2015-08-06
CN104736550A (en) 2015-06-24
JP6528029B2 (en) 2019-06-12
EP2877481B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
IN2015KN00492A (en)
NZ708727A (en) Conjugate compounds
WO2013120022A3 (en) Treatment of hypoglycemia
MD20150091A2 (en) Anti-viral compounds
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2017005834A (en) Aadc polynucleotides for the treatment of parkinson's disease.
TW201613901A (en) New compounds
WO2015085318A3 (en) Targeted adaptive vaccines
NZ700928A (en) Dna-pk inhibitors
MY165579A (en) Synthetic methods for spiro-oxindole compounds
MX2022001310A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds.
EA201490423A1 (en) METHODS AND COMPOSITIONS RELATED TO p62 FOR TREATMENT AND PREVENTION OF CANCER
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2020006237A (en) Compounds for treatment of diseases related to dux4 expression.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12014502032A1 (en) Treatment of brain cancer
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2014086453A8 (en) Azaheterobicyclic compounds
PH12017501872A1 (en) Methods of treating diseases
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
NZ613614A (en) Sphingoglycolipid compounds and uses